Sometimes the problems are simple--development teams just fail to write critical information down in their notebooks, "something they should have learned in college!" Ciurczak says. But the experts also make clear that practices associated with Quality by Design--namely, proactive risk assessment and data management--can eliminate problems in the early stages of development and facilitate later transfer. Perry notes how developers typically send data on successful process studies to their partners, but not data from failed studies that can be just as enlightening.
There is no such thing as “too much” or “too detailed” information. Such dedicated tools as assay summaries, detailed process descriptions, and bills of materials should be created and used . Other information from the sender, such as regulatory submissions, development reports, raw data, validation reports, etc., can be extremely useful. This work would have to be done anyway as part of the future process validation and to support regulatory submissions.
One of Somma's mantras is simplifying tech transfer, which seems to run counter to the idea of providing as much detailed information as possible. He, as well as Oracle's Arvindh Balakrishnan, explain how this paradoxical challenge can be overcome in a podcast which is now the lead feature on our PharmaQbD.com site.
The success or failure of tech transfer is hard to measure, but that doesn't mean that it shouldn't be a key focus of initiatives to accelerate and lessen the costs of drug development.
Posts
